Kavita Juneja
Company: Corcept Therepeutics
Job title: Senior Director, Head of Metabolic Therapeutic Development
Seminars:
Investigating Miricorilant, a Selective Glucocorticoid Receptor Modulator, for Treatment of NASH 1:00 pm
Developing miricorilant, a selective glucocorticoid receptor modulator, as a novel treatment for NASH Review efficacy of miricorilant in preclinical models of fatty liver disease and early clinical trials in patients with presumed NASH Next steps: Phase 2 development program for treatment of patients with non-cirrhotic NASHRead more
day: Seminar A- PM tracks